Literature DB >> 12476310

Studying the pathogenesis of BCR-ABL+ leukemia in mice.

Richard A Van Etten1.   

Abstract

Animal models of BCR-ABL+ leukemias have provided important new knowledge about the molecular pathophysiology of these diseases, and answered questions that are difficult or impossible to address using BCR-ABL-expressing cell lines or primary Ph+ leukemia samples from patients. The power of mouse models lies in their ability to recapitulate precisely the phenotypes of BCR-ABL+ leukemias in vivo, but this comes at the price of significant complexity. Here I review recent studies of leukemias induced in mice by BCR-ABL with an emphasis on the intricate nature of these diseases and the need for careful pathological and molecular analysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12476310     DOI: 10.1038/sj.onc.1206091

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis.

Authors:  Curtis J Henry; Andriy Marusyk; Vadym Zaberezhnyy; Biniam Adane; James DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

2.  Production of replication-defective retrovirus by transient transfection of 293T cells.

Authors:  L Cristina Gavrilescu; Richard A Van Etten
Journal:  J Vis Exp       Date:  2007-12-04       Impact factor: 1.355

Review 3.  Molecular genetics of B-precursor acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

4.  Impaired DNA replication within progenitor cell pools promotes leukemogenesis.

Authors:  Ganna Bilousova; Andriy Marusyk; Christopher C Porter; Robert D Cardiff; James DeGregori
Journal:  PLoS Biol       Date:  2005-11-15       Impact factor: 8.029

5.  Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.

Authors:  Melanie R Bui; Victoria Hodson; Tom King; Derek Leopold; Shaodong Dai; Valerie Fiolkoski; Sarah Oakes; Richard Duke; David Apelian; Alex Franzusoff; James DeGregori
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

6.  IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.

Authors:  Mo-Ying Hsieh; Richard A Van Etten
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

7.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

Authors:  M Golam Mohi; Christina Boulton; Ting-Lei Gu; David W Sternberg; Donna Neuberg; James D Griffin; D Gary Gilliland; Benjamin G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

8.  Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.

Authors:  Xiaomin Zheng; Claudia Oancea; Reinhard Henschler; Malcolm A S Moore; Martin Ruthardt
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

9.  CREB is a critical regulator of normal hematopoiesis and leukemogenesis.

Authors:  Jerry C Cheng; Kentaro Kinjo; Dejah R Judelson; Jenny Chang; Winston S Wu; Ingrid Schmid; Deepa B Shankar; Noriyuki Kasahara; Renata Stripecke; Ravi Bhatia; Elliot M Landaw; Kathleen M Sakamoto
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

10.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.